Replies to post #77350 on NorthWest Biotherapeutics Inc (NWBO)

[Do Due Dilligence]

I don't think it is that clear...what is clear is that there is a favourable bias for mensenchymal subtype but I would definitly not rule out efficacy on other patients.
It is also probable that they have tried to screen as many mesenchymal as possible since that find. We will see once all that stuff is unblinded.